While the capital raise strengthens Celldex’s balance sheet for clinical development, the lack of near-term catalysts or data readouts suggests limited immediate upside. Traders should monitor pipeline advancement and future dilution risk given the company's pre-revenue status.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $31.37entry
- T+1 · 7mo ago −0.06%α −0.13% · $31.35
- T+5 · 7mo ago +3.89%α −0.25% · $32.59
- T+20 · 7mo ago +4.46%α −4.52% · $32.77
- T+60 · 5mo ago +17.25%α +3.78% · $36.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approximately $345 million in gross proceeds. The capital will support the company's clinical-stage biotech pipeline focused on mast cell biology and immune system therapeutics.
Key Financial Metrics
Key Facts
- Celldex closed a public offering of 11,896,750 common shares, including full exercise of the underwriters' option for 1,551,750 additional shares.
- Offering price was $29.00 per share, resulting in gross proceeds of approximately $345 million.
- Proceeds will be used for general corporate purposes, including advancing Celldex’s clinical-stage pipeline in inflammatory, allergic, and autoimmune diseases.
- Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunners; LifeSci Capital and H.C. Wainwright as co-lead managers.
- The offering was made under an effective shelf registration (Form S-3, File No. 333-275300) and completed via prospectus supplement.
Financial Impact
$345 million in gross proceeds, with no immediate dilution impact factored into stock price post-offering
Risk Factors
- Dilution from the issuance of new shares could pressure stock price despite strong gross proceeds.
- As a clinical-stage biotech with no commercial products, Celldex remains highly dependent on trial outcomes and future funding rounds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268530 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers